Archived article
Please note that tax, investment, pension and ISA rules can change and the information and any views contained in this article may now be inaccurate.
Angle said its ability to offer megakaryocyte tests to its existing circulating tumor cells tests received a boost after the Queen Mary University of London was granted a European patent covering the measurement of the number of megakaryocytes in a patient blood sample as an assessment of the prognosis for prostate cancer.
Angle's Parsortix system was the only automated system that had demonstrated the capability of harvesting megakaryocytes -- the presence of which had been linked to survival in patients suffering from prostate cancer, the company said.
With Angle having an option agreement, exercisable up until 14 June 2021, with QMUL for an exclusive worldwide licence over the use of its megakaryocyte intellectual property, the grant of the European patent would protect the company's ability to offer a megakaryocyte-based test in Europe, Angle said.
Similar patents were being pursued in the United States and certain other major territories.
The protection of key intellectual property was an essential part of ANGLE's commercialisation strategy, the company said.
We will now be investigating the possibility of adding megakaryocyte tests to our existing circulating tumor cells tests as part of our sample-to-answer imaging solution under development, the company said.
At 8:59am: (LON:AGL) Angle PLC share price was +1p at 78.5p